id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-V-0275-0005,FDA,FDA-2015-V-0275,Variance Approval from FDA CDRH  to Intel Corporation,Other,Approval for Variance (VRA),2016-06-13T04:00:00Z,2016,6,2016-06-13T04:00:00Z,,2016-06-13T18:38:22Z,,0,0,090000648201d739
FDA-2015-V-0275-0004,FDA,FDA-2015-V-0275,Acknowledgement Letter from FDA DDM to Intel Corporation,Other,Acknowledgement Letter/Receipt,2015-12-30T05:00:00Z,2015,12,2015-12-30T05:00:00Z,,2015-12-30T18:41:03Z,,0,0,0900006481ddc836
FDA-2015-V-0275-0003,FDA,FDA-2015-V-0275,Variance Application from Intel Corporation,Other,Application for Variance (VAR),2015-12-30T05:00:00Z,2015,12,2015-12-30T05:00:00Z,,2015-12-30T18:39:51Z,,0,0,0900006481ddca7e
FDA-2015-V-0275-0001,FDA,FDA-2015-V-0275,Variance Application from Intel Corporation,Other,Application for Variance (VAR),2015-02-18T05:00:00Z,2015,2,2015-02-18T05:00:00Z,,2015-02-18T17:11:19Z,,0,0,09000064819e4e39
FDA-2015-V-0275-0002,FDA,FDA-2015-V-0275,Acknowledgement Letter from FDA DDM to Intel Corporation,Other,Acknowledgement Letter/Receipt,2015-02-18T05:00:00Z,2015,2,2015-02-18T05:00:00Z,,2015-02-18T17:13:48Z,,0,0,09000064819e4e3b